Answers are grounded in this paper and cite their sources.
Pharmacovigilance study characterizes adverse event reporting patterns in B-cell non-Hodgkin lymphoma, suggesting nuanced monitoring needs.
Background Rituximab and obinutuzumab share the CD20 target but are used across distinct B-cell non-Hodgkin lymphoma (B-NHL) subtypes, treatment backbones, and clinical eras. Their real-world adverse event (AE) reporting patterns remain incompletely characterized. Purpose To characterize AE reporting patterns for rituximab and obinutuzumab in B-NHL using FAERS, evaluate signal retention across histological subtype and calendar-period strata and after COVID-associated report exclusion, and describe serious outcome reporting patterns during the common-market period. Methods FAERS reports listing rituximab or obinutuzumab as the primary suspect drug with B-NHL indications from January 2004 to December 2024 were extracted. Disproportionality signals were evaluated using reporting odds ratios (RORs) and Bayesian Confidence Propagation Neural Network (BCPNN)-derived information components (ICs). Pooled B-NHL analyses identified candidate System Organ Class (SOC)- and Preferred Term (PT)-level reporting signals. Candidate signals were further evaluated across histological subtype and calendar-period strata and in a sensitivity analysis excluding reports containing COVID-associated PTs. Multivariable logistic regression assessed serious outcome reporting during the common-market period. Results In pooled B-NHL analyses, both drugs showed overlapping SOC-level reporting domains, including hematologic, infection-related, respiratory, vascular, and hepatobiliary disorders. Infusion related reaction was the most uniformly retained PT-level signal for both drugs, whereas cytopenia-related hematologic signals showed broad but non-uniform retention. Infection-related, respiratory, and neoplasm-related findings required contextual interpretation according to reporting era, histological subtype, component PT heterogeneity, or survivorship background. Most pooled candidate clinical PT-level signals remained signal-positive after exclusion of COVID-associated reports. Obinutuzumab reports had higher adjusted odds of serious outcome reporting during 2014–2019 (aOR 1.59, 95% CI 1.42–1.77) but not during 2020–2024 (aOR 1.03, 95% CI 0.94–1.12), with a significant drug-by-period interaction. Conclusion FAERS reports involving rituximab and obinutuzumab in B-NHL showed overlapping AE reporting domains, but pooled signals differed in retention across clinical and reporting contexts. Infusion related reaction was the clearest consistently retained PT-level finding, whereas cytopenia-related hematologic events formed a broad but non-uniform reporting domain. Signal-retention analyses may help prioritize pharmacovigilance hypotheses and setting-specific AE monitoring, but these reporting patterns require validation in longitudinal data sources and should not be interpreted as causal or direct comparative safety estimates.
No takes yet. Share an insight, caveat, or question.
Ma et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: